%0 Journal Article
%A Körber, Stefan
%A Röhrich, Manuel
%A Walkenbach, Leon
%A Liermann, Jakob
%A Choyke, Peter L
%A Fink, Christoph
%A Schroeter, Cathrin
%A Spektor, Anna-Maria
%A Herfarth, Klaus
%A Walle, Thomas
%A Calais, Jeremie
%A Kauczor, Hans-Ulrich
%A Jaeger, Dirk
%A Debus, Jürgen
%A Haberkorn, Uwe
%A Giesel, Frederik L
%T Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
%J Journal of nuclear medicine
%V 64
%N 11
%@ 0097-9058
%C New York, NY
%I Soc.
%M DKFZ-2023-01829
%P 1712-1720
%D 2023
%Z #EA:E050# / 2023 Nov;64(11):1712-1720
%X Since the development of fibroblast activation protein-targeted radiopharmaceuticals, 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for detecting primary and metastatic lesions in many types of tumors. However, there is currently a lack of reliable data regarding the clinical impact of this family of probes. To address this gap, the present study aimed to analyze the clinical impact of 68Ga-FAPI PET/CT by examining a large cohort of patients with various tumors. Methods: In total, 226 patients (137 male and 89 female) were included in this retrospective analysis. Pancreatic cancer and head and neck cancers were the most common tumor types in this cohort. TNM stage and oncologic management were initially determined with gold standard imaging, and these results were compared with 68Ga-FAPI PET/CT. Changes were classified as major and minor. Results: For 42
%K FAPI (Other)
%K PET/CT (Other)
%K management (Other)
%K radiation therapy (Other)
%K staging (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37678928
%R 10.2967/jnumed.123.266046
%U https://inrepo02.dkfz.de/record/282683